Modeling and Modulating Mechanisms of Escape, Avoidance, and Approach in the Anxiety Disorder Spectrum
焦虑症谱系中逃避、回避和接近的建模和调节机制
基本信息
- 批准号:10576356
- 负责人:
- 金额:$ 20.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-02 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAdjuvant TherapyAmbulatory CareAmygdaloid structureAnhedoniaAnimalsAnxietyAreaAversive StimulusBasic ScienceBehaviorClinicalClinical ResearchCognitive TherapyCollaborationsComputer ModelsConflict (Psychology)Coping BehaviorCorpus striatum structureDataDecision MakingDevelopmentDevelopment PlansDiagnosticDiseaseDisease remissionDorsalDropoutEducational workshopEnsureFosteringFrightFunctional Magnetic Resonance ImagingFutureGoalsGrantHumanImpairmentIndividualInstitutionInternationalInterventionKnowledgeLaboratoriesMajor Depressive DisorderMapsMediatingMedicalMental DepressionMental Health ServicesMental disordersMentored Patient-Oriented Research Career Development AwardMentorsMentorshipMethodsModelingMotivationNational Institute of Mental HealthNeurosciencesOutcomeParticipantPatientsPatternPhysiologyPrefrontal CortexPreparationProductivityPsychiatryPublicationsReflex actionResearchResearch Domain CriteriaResearch MethodologyResearch PersonnelRewardsScienceSouth CarolinaStimulusSymptomsTechniquesTestingTrainingTranslational ResearchTreatment outcomeUniversitiesVentral StriatumWorkWritinganxiety spectrum disordersanxiousapproach avoidance behavioravoidance behaviorcareercareer developmentclinical practicecopingcosteffective therapyevidence basehands on researchimprovedimproved outcomemultimodalityneural circuitneuroregulationnoninvasive brain stimulationnovelpre-clinicalprecision medicinepreventreduce symptomsrepetitive transcranial magnetic stimulationresponseskillssubstance misusesymposiumtherapy outcometooltranslational applications
项目摘要
PROJECT ABSTRACT
The proposed K23 Mentored Patient-Oriented Research Career Development Award launches a line of work
aiming to comprehensively target mechanisms of avoidance in anxiety and other disorders; and, it provides Dr.
Christopher Sege with skills necessary to becoming a leading clinical researcher. Dr. Sege’s primary clinical
research career goal is to use cutting-edge translational science to improve mental health care by targeting
precise disorder mechanisms. Need for this research is significant and consistent with NIMH priorities and the
RDoC framework. Avoidance is a core target of anxiety and related disorder treatment, but avoidant behaviors
often persist after symptom reduction and keep many from engaging in treatment at all. Novel methods to
target multiple motive drivers of avoidance early in treatment are needed to improve retention and outcome
especially for the 20% of individuals who do not benefit from and 40% who do not complete treatment. Basic
science provides critical clues as to the multiple mechanisms of real-world avoidance that may be indirectly or
inadequately addressed by current treatment techniques. Crucial goals of work proposed here is to determine
how these mechanisms drive clinical behavior and support subsequent work that develops direct intervention
tools. The proposed project uses direct neurostimulation (repetitive transcranial magnetic stimulation; rTMS) in
concert with precise experimental methods to test how specific reactive (escape) and proactive (avoidance)
coping neurocircuits can be modulated to alter downstream fear and approach-avoid decision-making.
Subsequent R-level applications build on this work to determine coping profiles of treatment completers versus
non-completers, and to test how profiles can be more precisely targeted to improve outcomes. A team of
expert mentors (George, Liu, McTeague, Mobbs, Uhde) will use their extensive knowledge in research-based
and clinical neurostimulation, advanced fMRI analysis and research methods, and creation of translational
science-informed treatment adjuvants to support Dr. Sege in his development. Mentorship, hands-on research
tutorials, coursework, seminars/ workshops, and international conference attendance afforded by the K23 will
ensure that Dr. Sege achieves his career goals to: 1) develop expertise in cutting-edge neurostimulation for
research and clinical use, 2) develop expertise in fMRI analysis and research tools for use in concert with
rTMS to more precisely target ecologically-relevant avoidance behavior, and; 3) develop expertise in creating
adjuvants that improve cognitive behavior therapy outcomes through application of translational science. The
proposed K23 will also foster development in areas of publication, grant writing, and inter-departmental
collaboration, all at an institution – the Medical University of South Carolina – which has a strong track record
and commitment to early stage investigators. Proposed K23 activities will prepare Dr. Sege to become a
cutting-edge clinical researcher and a leader in the development of a precision medicine of psychiatry.
项目摘要
拟议的K23指导了以患者为导向的研究职业发展奖,启动了一系列工作
旨在全面针对焦虑和其他疾病中的回避机制;而且,它提供了博士。
克里斯托弗·塞格(Christopher Sege)具有成为领先的临床研究人员所必需的技能。 Sege博士的主要临床
研究职业目标是使用尖端的翻译科学来通过靶向来改善心理保健
精确的疾病机制。对这项研究的需求非常重要,并且与NIMH的优先级一致,
RDOC框架。避免是动画和相关障碍治疗的核心目标,但回避行为
症状减轻后通常会持续存在,并完全防止许多人从事治疗。新方法
需要在治疗早期的早期避免的目标驱动因素以改善保留率和结果
尤其是对于20%的人中没有受益的人,而没有完成治疗的40%。基本的
科学为可能是间接或
当前的治疗技术无法充分解决。这里提出的工作的关键目标是确定
这些机制如何推动临床行为并支持后来发展直接干预的工作
工具。拟议的项目使用直接的神经刺激(重复的经颅磁刺激; RTMS)
使用精确的实验方法进行音乐会,以测试特定反应性(逃脱)和主动(避免)
可以调节应对神经环节以改变下游的恐惧和避免进近的决策。
随后的R级应用程序以这项工作为基础,以确定治疗完成者的应对配置文件
未完成的人,并测试如何更精确地针对改善预后。一个团队
专家导师(George,Liu,McTeague,MOBBS,UHDE)将在基于研究的基于研究中的广泛知识
以及临床神经刺激,高级功能磁共振成像分析和研究方法以及转化的创建
科学知识的治疗调节器,以支持Sege博士的发展。指导,动手研究
K23提供的教程,课程,课程/讲习班和国际会议出席
确保Sege博士实现自己的职业目标:1)在尖端神经刺激方面发展专业知识
研究和临床用途,2)在fMRI分析和研究工具方面开发专业知识,以便与
RTMS更精确地针对与生态相关的避免行为,并且; 3)发展创建专业知识
通过应用转化科学改善认知行为疗法结果的佐剂。这
拟议的K23还将促进出版,赠款写作和部门间的发展
合作,所有机构 - 南卡罗来纳州医科大学 - 有很强的往绩
并致力于早期调查人员。拟议的K23活动将使Sege博士做好准备成为一个
尖端的临床研究人员和精神病学精确医学发展的领导者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Christopher Sege其他文献
Christopher Sege的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Christopher Sege', 18)}}的其他基金
Modeling and Modulating Mechanisms of Escape, Avoidance, and Approach in the Anxiety Disorder Spectrum
焦虑症谱系中逃避、回避和接近的建模和调节机制
- 批准号:
10215704 - 财政年份:2021
- 资助金额:
$ 20.9万 - 项目类别:
Modeling and Modulating Mechanisms of Escape, Avoidance, and Approach in the Anxiety Disorder Spectrum
焦虑症谱系中逃避、回避和接近的建模和调节机制
- 批准号:
10362709 - 财政年份:2021
- 资助金额:
$ 20.9万 - 项目类别:
相似国自然基金
穿透性靶向胰腺癌内cDC1的纳米佐剂调控溶酶体逃逸促进放疗诱导ICD的机制研究
- 批准号:82303680
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
多级改造的工程化外泌体自佐剂疫苗平台实现鼻上皮细胞感染拟态和粘膜递送的研究
- 批准号:32371440
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
展示PD-L1抗体的纳米锰佐剂联合放疗以诱导原位肿瘤疫苗的产生及其机制的探究
- 批准号:32371518
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
靶向FPPS的双磷酸疫苗佐剂的开发
- 批准号:82341040
- 批准年份:2023
- 资助金额:100 万元
- 项目类别:专项基金项目
应用于冠状病毒广谱疫苗开发的新型全链式免疫增强型佐剂研究
- 批准号:82341036
- 批准年份:2023
- 资助金额:110 万元
- 项目类别:专项基金项目
相似海外基金
Cellular mechanisms for the degeneration and aging of human rotator cuff tears
人类肩袖撕裂变性和衰老的细胞机制
- 批准号:
10648672 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别:
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
- 批准号:
10710883 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别:
Sonodynamic therapy using MRI-guided focused ultrasound in combination with 5-aminolevulinic acid to treat recurrent glioblastoma multiforme
使用 MRI 引导聚焦超声联合 5-氨基乙酰丙酸的声动力疗法治疗复发性多形性胶质母细胞瘤
- 批准号:
10699858 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别:
Project 2: Mechanisms of Resistance to Neoantigen Vaccines in PDAC
项目2:PDAC新抗原疫苗耐药机制
- 批准号:
10708575 - 财政年份:2023
- 资助金额:
$ 20.9万 - 项目类别: